Acyclovir for Varicella Zoster Infection

Claude Fanelli, Fred R. Sattler, Henry H. Balfour, Bonnie Bean, Oscar L. Laskin, Richard F. Ambinder, Joel D. Meyers, James C. Wade, John A. Zaia, Dorothee Aeppli, L. Edward Kirk, Anthony C. Segreti, Ronald E. Keeney

Research output: Contribution to journalLetter

Abstract

To the Editor: Balfour et al. demonstrated in their placebo-controlled study that acyclovir prevented cutaneous or visceral dissemination of herpes zoster infection in immunocompromised patients, even if treatment was begun more than 72 hours after the first appearance of vesicles (June 16 issue).1 However, the authors combined the results of therapy in patients with infection localized to a single dermatome and in those with generalized cutaneous disease before treatment. When we analyzed their results in these two groups separately, we found no statistical difference in outcome between patients treated with acyclovir and those given placebo, if treatment was begun after.

Original languageEnglish (US)
Pages (from-to)987-988
Number of pages2
JournalNew England Journal of Medicine
Volume310
Issue number15
DOIs
StatePublished - Apr 12 1984

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Acyclovir for Varicella Zoster Infection'. Together they form a unique fingerprint.

  • Cite this

    Fanelli, C., Sattler, F. R., Balfour, H. H., Bean, B., Laskin, O. L., Ambinder, R. F., Meyers, J. D., Wade, J. C., Zaia, J. A., Aeppli, D., Kirk, L. E., Segreti, A. C., & Keeney, R. E. (1984). Acyclovir for Varicella Zoster Infection. New England Journal of Medicine, 310(15), 987-988. https://doi.org/10.1056/NEJM198404123101513